Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.
Advanced Oxidation Protein Products as a Novel Marker of Oxidative Stress in Postmenopausal Osteoporosis.
复制标题
高级氧化蛋白产品作为绝经后骨质疏松症氧化应激的新标志物
DOI：
10.12659/msm.894347
复制
发表时间：
2015-08-18
期刊：
影响因子：
--
通讯作者：
Chen JT
中科院分区：
文献类型：
--
作者：
Wu Q;Zhong ZM;Pan Y;Zeng JH;Zheng S;Zhu SY;Chen JT
背景高级氧化蛋白产物（AOPP）被认为是氧化介导的蛋白质损伤的新标志物。本研究旨在调查绝经后骨质疏松女性血浆中AOPPs的水平，并确定AOPPs积累与腰椎骨矿物质命运（BMD）或骨转换标志物之间的关系。材料/方法腰椎 BMD 通过双能 X 射线吸收法测量。通过分光光度法测量作为蛋白质氧化损伤标志物的血浆AOPP水平和作为脂质过氧化标志物的丙二醛(MDA)水平。使用 ELISA 试剂盒对骨转换的 2 种特异性标记物、骨特异性碱性磷酸酶 (BALP) 和抗酒石酸酸性磷酸酶 5b (TRACP 5b) 的浓度进行定量。结果 我们招募了 60 名符合世界卫生组织 (WHO) 骨质疏松症 (OP) 诊断标准的绝经后妇女和 60 名没有 OP 的绝经后妇女。与对照组相比，绝经后骨质疏松女性血浆AOPPs（P<0.001）、BALP（P<0.001）和TRACP 5b（P<0.001）水平显着升高，但两组间MDA差异无统计学意义（P=0.124）。在绝经后骨质疏松女性和所有受试者中，血浆 AOPP 水平与腰椎 BMD 呈负相关，与骨转换标志物呈正相关。然而，血浆 MDA 水平与腰椎 BMD 或骨转换标志物无关。结论 在绝经后骨质疏松女性中，AOPP 升高与 BMD 降低和骨转换标志物增加相关。由于 AOPP 稳定且易于检测，因此可用作简单的血浆标记物来预测绝经后 OP 的严重程度。
Background Advanced oxidation protein products (AOPPs) are acknowledged as a novel marker of oxidation-mediated protein damage. This study aimed to investigate the plasma levels of AOPPs in postmenopausal osteoporotic women, and to determine the relationship between AOPPs accumulation and lumbar bone mineral destiny (BMD) or bone turnover markers. Material/Methods Lumbar BMD was measured by dual-energy X-ray absorptiometry. Plasma AOPPs levels as a marker of protein oxidation damage and malondialdehyde (MDA) levels as a marker of lipid peroxidation were measured by spectrophotometry. The concentrations of 2 specific markers of bone turnover, bone-specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase5b, (TRACP 5b) were quantified using ELISA kits. Results We recruited 60 postmenopausal women meeting osteoporosis (OP) diagnostic criteria of World Health Organization (WHO) and 60 postmenopausal women without OP. Plasma levels of AOPPs (P<0.001), BALP (P<0.001) and TRACP 5b (P<0.001) were statistically significantly increased in the postmenopausal osteoporotic women compared with controls, but there was no statistically significant difference in MDA (P=0.124) between the 2 groups. Plasma AOPPs levels were negatively correlated with lumbar BMD and positively correlated with bone turnover markers both in postmenopausal osteoporotic women and in all subjects. However, plasma MDA levels were not correlated with lumbar BMD or bone turnover markers. Conclusions In postmenopausal osteoporotic women elevated AOPPs is associated with reduced BMD and increased bone turnover markers. Because AOPPs is stable and easy to detect it may be used as a simple plasma marker to predict the severity of postmenopausal OP.